Alpine Immune Sciences (NASDAQ:ALPN) Reaches New 1-Year High at $64.58

Alpine Immune Sciences, Inc. (NASDAQ:ALPN)’s stock price reached a new 52-week high during trading on Monday . The company traded as high as $64.58 and last traded at $64.58, with a volume of 1793587 shares changing hands. The stock had previously closed at $64.55.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on ALPN shares. Morgan Stanley reiterated an “equal weight” rating and set a $65.00 price target (up previously from $47.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. TD Cowen reiterated a “hold” rating on shares of Alpine Immune Sciences in a report on Tuesday, April 16th. Wolfe Research restated a “peer perform” rating on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Oppenheimer restated an “outperform” rating and set a $44.00 price objective (up previously from $33.00) on shares of Alpine Immune Sciences in a research report on Tuesday, March 19th. Finally, Leerink Partnrs downgraded shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 11th. Eight investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $50.33.

Alpine Immune Sciences Price Performance

The company’s 50-day simple moving average is $41.49 and its two-hundred day simple moving average is $25.72.

Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The business had revenue of $30.85 million for the quarter, compared to the consensus estimate of $6.90 million. On average, sell-side analysts predict that Alpine Immune Sciences, Inc. will post -1.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Alpine Immune Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC lifted its holdings in Alpine Immune Sciences by 745.5% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,312 shares in the last quarter. AJOVista LLC purchased a new stake in Alpine Immune Sciences during the fourth quarter valued at approximately $64,000. Barclays PLC lifted its position in Alpine Immune Sciences by 44.3% during the third quarter. Barclays PLC now owns 9,126 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 2,801 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Alpine Immune Sciences by 411.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,490 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 4,417 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in Alpine Immune Sciences by 75.8% during the 3rd quarter. New York State Common Retirement Fund now owns 9,634 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 4,155 shares in the last quarter. 75.17% of the stock is owned by hedge funds and other institutional investors.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.